Detlev Biniszkiewicz, PhD
Detlev is a member of the Board of Directors and the former President and Chief Executive Officer of Surface Oncology. He brings over fifteen years of industry experience discovering and developing transformative cancer medicines. Prior to Surface, he was a member of the AstraZeneca Oncology leadership team responsible for strategy, licensing, and academic & clinical collaborations. He led the aggressive and successful strategy to rebuild AZ pipeline through investments in immuno-oncology, DNA repair, and genetic diseases. His group executed on more than 20 licensing deals, and 150 academic & clinical collaborations. As part of the AZ Oncology leadership, he was deeply involved in developing Tagrisso™ (AZD9291) and Lynparza™ (olaparib), approved treatments for patients suffering from Lung and Ovarian cancer. Previously, Detlev was the Global Head of Portfolio and Head of Strategy at the Novartis Institute for Biomedical Research. Earlier in his career he was Principal and member of the pharmaceutical practice at The Boston Consulting Group. Detlev also serves on Surface Oncology’s Board of Directors. He completed his academic education and fellowship with Rudolf Jaenisch at the Whitehead Institute (MIT) where he studied embryonic stem cells and epigenetic changes in cancer.